To begin with, 2% of patients developed de novo arterial hypertension during the study year, which can be explained by the interference SARS-CoV-2 has over the rennin angiotensin system (RAS), with angiotensin-converting enzyme 2 (ACE2) being the major counter-regulatory mechanism for the main axis of the RAS, and critical for the control of blood pressure and electrolyte balance. Here, ACE2 is linked to Hypertension.